Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia

Journal of Immunology

Volumn 175, Issue 12, 2005, Pages 7898-7904

  Liu, Ruolan ^a   Cava, Antonio La ^b   Bai, Xue Feng ^c   Jee, Youngheun ^a   Price, Mary ^a   Campagnolo, Denise I ^a   Christadoss, Premkumar ^d   Vollmer, Timothy L ^a   Van Kaer, Luc ^e   Shi, Fu Dong ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; AUTOANTIGEN; CD4 ANTIGEN; CHOLINERGIC RECEPTOR; GLYCOLIPID; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; MYASTHENIA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION;

EID: 29144487073     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.12.7898     Document Type: Article

References (26)

1. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388.
2. Van Kaer, L. 2005. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5: 31-42.
3. Hammond, K. J., and M. Kronenberg. 2003. Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr. Opin. Immunol. 15: 683-689.
4. Vincent, A., and D. B. Drachman. 2002. Myasthenia gravis. Adv. Neurol. 88: 159-188.
5. Yang, H., M. Kala, B. G. Scott, E. Goluszko, H. A. Chapman, and P. Christadoss. 2005. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J. Immunol. 174: 1729-1737.
6. Kopf, M., G. Le Gros, M. Bachmann, M. C. Lamers, H. Bluethmann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362: 245-248.
7. Mendiratta, S. K., W. D. Martin, S. Hong, A. Boesteanu, S. Joyce, and L. Van Kaer. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6: 469-477.
8. Shi, F. D., H. Li, H. Wang, X. Bai, P. H. van der Meide, H. Link, and H. G. Ljunggren. 1999. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J. Immunol 162: 5757-5763.
9. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
10. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201: 723-735.
11. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
12. Shi, F. D., H. B. Wang, H. Li, S. Hong, M. Taniguchi, H. Link, L. Van Kaer, and H. G. Ljunggren. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1: 245-251.
13. Hong, S., M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, et al. 2001. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7: 1052-1056.
14. Balasa, B., C. Deng, J. Lee, P. Christadoss, and N. Sarvetnick. 1998. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161: 2856-2862.
15. Ostlie, N., M. Milani, W. Wang, D. Okita, and B. M. Conti-Fine. 2003. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J. Immunol. 170: 604-612.
16. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6: 345-352.
17. Schwanz, R. H. 2005. Natural regulatory T cells and self-tolerance. Nat. Immunol. 6: 327-330.
18. + regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 101: 15434-15439.
19. Shevach, E. M. 2000. Regulatory T cells in autoimmunity. Annu. Rev. Immunol 18: 423-449.
20. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169: 4712-4716.
21. + regulatory T cells? Eur. J. Immunol. 35: 1193-1200.
22. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105: 735-741.
23. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979.
24. + regulatory T cells. Proc. Natl. Acad. Sci. USA 102: 5150-5155.
25. + T cells in patients with MS; effects of glatiramer Acetate. In 57th Annual Neurology Meeting (American Academy), April 9-16, 2005, Vol. 64. American Academy of Neurology, St. Paul, MN, p. A269.
26. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. USA 102: 6449-6454.